Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc chief business officer Anne Erickson reported a tax-related disposition of common stock. On 12/14/2025, 62,960 shares of Savara common stock were withheld by the company at a price of $6.92 per share to satisfy her tax liability upon vesting of previously awarded restricted stock units. After this withholding transaction, she directly beneficially owns 371,712 Savara shares.
Savara Inc. director Richard Hawkins reported an equity award of 40,000 restricted stock units (RSUs) of Savara common stock dated December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues his service with the company, and each RSU represents a right to receive one share of common stock. He has elected to defer delivery of the vested shares until after his service with Savara ends. Following this grant, he beneficially owns 161,326 shares of Savara common stock in direct ownership.
Savara Inc director David Ramsay reported the acquisition of 40,000 restricted stock units (RSUs) tied to the company’s common stock on December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues to serve with Savara, and each RSU represents a contingent right to receive one share of common stock. The transaction price was listed as $0.00, indicating no cash was paid for the award. Following this grant, Ramsay beneficially owns 2,553,642 shares of Savara common stock in direct ownership.
Savara Inc director Joseph S. McCracken reported acquiring 40,000 shares of common stock on December 9, 2025 at a reported price of $0.00 per share. Following this equity award, he beneficially owns 300,837 shares of Savara common stock directly.
The 40,000 shares are described as restricted stock units (RSUs) that vest in full on December 9, 2026, if he continues his service with the company. Each RSU represents a contingent right to receive one share of common stock, and he has elected to defer receipt of these shares so that they will be delivered after his service with Savara ends.
Savara Inc. (SVRA) director reports stock option exercise. A Savara director filed a Form 4 reporting the exercise of a stock option for 5,860 shares of common stock on 11/14/2025 at an exercise price of $1.46 per share. After this transaction, the director directly holds 121,326 shares of Savara common stock. The related stock option, which vested in twelve equal quarterly installments beginning on March 15, 2016, has now been fully exercised, leaving 0 derivative securities beneficially owned.
Savara Inc. (SVRA) launched a primary offering of 23,809,524 shares of common stock and pre-funded warrants to purchase 7,142,857 shares. The shares are priced at $4.20 and the pre-funded warrants at $4.199 with a $0.001 exercise price. Gross proceeds are $129,992,857, with underwriting discounts of $7,800,000, for net proceeds before expenses of $122,192,857. The company estimates net proceeds of about $121.7 million after expenses.
The underwriters have a 30‑day option to buy up to 4,642,857 additional shares; if fully exercised, net proceeds before expenses would be $140,522,857. Savara plans to use the funds for working capital and general corporate purposes, including advancing MOLBREEVI toward regulatory approval, building commercialization infrastructure and supply, and launch preparation in the U.S. and EU.
The company also disclosed a purchase and sale agreement with RTW Investments under which Savara would receive $75.0 million upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered royalties on U.S. net sales, capped at $187.5 million.
Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.
The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.
Savara Inc. (SVRA) launched a primary offering of common stock and pre-funded warrants under a preliminary prospectus supplement. The company may sell common shares and, for certain existing large investors, pre-funded warrants with a $0.001 per-share exercise price. SVRA’s stock last closed at $4.41 on Nasdaq. The underwriters have a 30‑day option to purchase additional shares. Proceeds are intended for working capital and general corporate purposes, including MOLBREEVI clinical, regulatory, manufacturing, and U.S./EU launch preparations.
As context, shares outstanding were 172,836,922 as of June 30, 2025; this is a baseline figure, not the amount being offered. Pre-funded warrants are exercisable at any time, include 9.99% (up to 19.99% with notice) ownership limits, and will not be listed.
Recent development: SVRA entered a purchase and sale agreement with funds managed by RTW Investments, LP for $75.0 million payable upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered U.S. sales royalties ranging from 7.0% to 1.0% (with a 9.5% tier if a prior-year threshold is not met) until the Purchaser receives $187.5 million. A portion of the payment must repay outstanding indebtedness, and the agreement includes customary covenants and a lien on specified IP assets at closing.
Savara Inc. (SVRA) launched a primary offering of common stock and pre-funded warrants under a preliminary prospectus supplement. The company may sell common shares and, for certain existing large investors, pre-funded warrants with a $0.001 per-share exercise price. SVRA’s stock last closed at $4.41 on Nasdaq. The underwriters have a 30‑day option to purchase additional shares. Proceeds are intended for working capital and general corporate purposes, including MOLBREEVI clinical, regulatory, manufacturing, and U.S./EU launch preparations.
As context, shares outstanding were 172,836,922 as of June 30, 2025; this is a baseline figure, not the amount being offered. Pre-funded warrants are exercisable at any time, include 9.99% (up to 19.99% with notice) ownership limits, and will not be listed.
Recent development: SVRA entered a purchase and sale agreement with funds managed by RTW Investments, LP for $75.0 million payable upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered U.S. sales royalties ranging from 7.0% to 1.0% (with a 9.5% tier if a prior-year threshold is not met) until the Purchaser receives $187.5 million. A portion of the payment must repay outstanding indebtedness, and the agreement includes customary covenants and a lien on specified IP assets at closing.
Savara Inc. (SVRA) launched a primary offering of common stock and pre-funded warrants under a preliminary prospectus supplement. The company may sell common shares and, for certain existing large investors, pre-funded warrants with a $0.001 per-share exercise price. SVRA’s stock last closed at $4.41 on Nasdaq. The underwriters have a 30‑day option to purchase additional shares. Proceeds are intended for working capital and general corporate purposes, including MOLBREEVI clinical, regulatory, manufacturing, and U.S./EU launch preparations.
As context, shares outstanding were 172,836,922 as of June 30, 2025; this is a baseline figure, not the amount being offered. Pre-funded warrants are exercisable at any time, include 9.99% (up to 19.99% with notice) ownership limits, and will not be listed.
Recent development: SVRA entered a purchase and sale agreement with funds managed by RTW Investments, LP for $75.0 million payable upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered U.S. sales royalties ranging from 7.0% to 1.0% (with a 9.5% tier if a prior-year threshold is not met) until the Purchaser receives $187.5 million. A portion of the payment must repay outstanding indebtedness, and the agreement includes customary covenants and a lien on specified IP assets at closing.
Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.
Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.
Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.
Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.
Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.
Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.
Savara Inc. (SVRA) Form 4: The company’s Chief Medical Officer reported equity awards on 10/20/2025. The filing shows an acquisition of 35,000 restricted stock units (RSUs) at a price of $0.00, lifting directly held common shares to 190,000 following the transaction. The RSUs vest in full on 10/17/2027, each converting into one share upon vesting.
Separately, the officer received a stock option for 70,000 shares with an exercise price of $4.11 and an expiration on 10/20/2035. This option vests in sixteen equal quarterly installments beginning 10/17/2025. These are routine compensatory awards and do not indicate open‑market buying or selling.